Skip to main navigation

AnaptysBio

Investor Relations

  • About
    • Overview
    • Strategy
    • Senior Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Contact
  • Science
    • Immune Cell Modulation
    • Anaptys Publications and Relevant Literature
  • Pipeline
    • Overview
    • ANB032
    • Rosnilimab
    • ANB033
    • ANB101
    • Imsidolimab
    • Partnerships
  • Investors / News
    • Overview
    • News
    • Events
    • Presentations
    • Governance
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Investor FAQs
    • Contact
  • Careers
    • Overview
    • Job Openings
    • Core Values
    • Total Reward Program Highlights
    • AnaptysBio Culture
  • Contact
Toggle

Event Details

AnaptysBio, Inc. BTLA Agonist (ANB032) R&D Event

May 25, 2023 at 4:15 PM EDT

Click here for webcast

Supporting Materials

View Presentation 5 MB

Tools

  • Print

    Print
  • Email

    Email
  • RSS Feeds

    RSS Feeds
  • Email Alerts

    Email Alerts
  • Investor Contact

    Investor Contact
  • Document Request

    Document Request
 

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
(858) 362-6295 (ph)
info@anaptysbio.com
  • clear
  • clear

Quick Links

  • About
  • Science
  • Investors / News
  • Careers
  • Contact

Pipeline

  • ANB032
  • Rosnilimab
  • ANB033
  • ANB101
  • Imsidolimab
  • Partnerships
© 2023 AnaptysBio, Inc. All Rights Reserved.
Privacy Policy  |  Terms Of Use